FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001468622> ?p ?o ?g. }

• W2001468622 endingPage "2300" @default.
• W2001468622 startingPage "2290" @default.
• W2001468622 abstract "The neurokinin-1 antagonist aprepitant (EMEND; Merck Research Laboratories, West Point, PA) has been shown to reduce chemotherapy-induced nausea and vomiting when it is given with a 5-hydroxytryptamine-3 receptor antagonist and dexamethasone. The current study sought to define the most appropriate dose regimen of oral aprepitant.This multicenter, randomized, double-blind, placebo-controlled study was conducted in patients with cancer who were receiving initial cisplatin (> or = 70 mg/m(2)) and standard antiemetic therapy (intravenous ondansetron plus oral dexamethasone). Patients were randomized to receive standard therapy plus either aprepitant 375 mg on Day 1 and 250 mg on Days 2-5, aprepitant 125 mg on Day 1 and 80 mg on Days 2-5, or placebo. Due to an apparent interaction with dexamethasone suggested by pharmacokinetic data obtained while the study was ongoing, the aprepitant 375/250 mg dose was discontinued and replaced with aprepitant 40 mg on Day 1 and 25 mg on Days 2-5, and a new randomization schedule was generated. Patients recorded nausea and emesis in a diary. The primary endpoint was complete response (no emesis and no rescue therapy), which was analyzed using an intent-to-treat approach with data obtained after the dose adjustment. Treatment comparisons were made using logistic regression models. Tolerability was assessed by reported adverse events and physical and laboratory assessments, and included all available data.The percentages of patients who achieved a complete response in the overall study period were 71.0% for the aprepitant 125/80-mg group (n = 131 patients), 58.8% for the aprepitant 40/25-mg group (n = 119 patients), and 43.7% for the standard therapy group (n = 126 patients; P < 0.05 for either aprepitant regimen vs. standard therapy). Rates for Day 1 were 83.2% for the aprepitant 125/80-mg group, 75.6% for aprepitant 40/25-mg group, and 71.4% for the standard therapy group (P < 0.05 for aprepitant 125/80 mg vs. standard therapy), and rates on Days 2-5 were 72.7% for the aprepitant 125/80-mg group, 63.9% for the aprepitant 40/25-mg group, and 45.2% for the standard therapy group (P < 0.01 for either aprepitant group vs. standard therapy). The efficacy of the aprepitant 375/250-mg regimen was similar to that of the aprepitant 125/80-mg regimen. The overall incidence of adverse events was generally similar across treatment groups: 85% in the aprepitant 375/250-mg group (n = 34 patients), 76% in the aprepitant 125/80-mg group (n = 214 patients), 71% in the aprepitant 40/25-mg group (n = 120 patients), and 72% in the standard therapy group (n = 212 patients), with the exception of a higher incidence of infection in the aprepitant 125/80-mg group (13%) compared with the standard therapy group (4%).When it was added to a standard regimen of intravenous ondansetron and oral dexamethasone in the current study, aprepitant reduced chemotherapy-induced nausea and vomiting and was generally well tolerated, although increases in infection were noted that were assumed to be due to elevated dexamethasone levels as a result of the pharmacokinetic interaction. The aprepitant 125/80-mg regimen had the most favorable benefit:risk profile." @default.
• W2001468622 created "2016-06-24" @default.
• W2001468622 creator A5002258748 @default.
• W2001468622 creator A5015616162 @default.
• W2001468622 creator A5024094034 @default.
• W2001468622 creator A5028379207 @default.
• W2001468622 creator A5034364804 @default.
• W2001468622 creator A5037398995 @default.
• W2001468622 creator A5045814115 @default.
• W2001468622 creator A5048487071 @default.
• W2001468622 creator A5061133224 @default.
• W2001468622 creator A5063230516 @default.
• W2001468622 creator A5073906112 @default.
• W2001468622 date "2003-04-17" @default.
• W2001468622 modified "2023-10-18" @default.
• W2001468622 title "Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting" @default.
• W2001468622 cites W1530830778 @default.
• W2001468622 cites W158409069 @default.
• W2001468622 cites W1860985526 @default.
• W2001468622 cites W1876492466 @default.
• W2001468622 cites W1881601848 @default.
• W2001468622 cites W1963685566 @default.
• W2001468622 cites W1966546066 @default.
• W2001468622 cites W1975347539 @default.
• W2001468622 cites W1979822488 @default.
• W2001468622 cites W1983413945 @default.
• W2001468622 cites W2002726388 @default.
• W2001468622 cites W2008395275 @default.
• W2001468622 cites W2023400373 @default.
• W2001468622 cites W2046417971 @default.
• W2001468622 cites W2049256989 @default.
• W2001468622 cites W2067747375 @default.
• W2001468622 cites W2070998568 @default.
• W2001468622 cites W2119544301 @default.
• W2001468622 cites W2125540170 @default.
• W2001468622 cites W2132936183 @default.
• W2001468622 cites W2136818862 @default.
• W2001468622 cites W2160465588 @default.
• W2001468622 cites W2321102680 @default.
• W2001468622 cites W2324983656 @default.
• W2001468622 cites W2338394838 @default.
• W2001468622 doi "https://doi.org/10.1002/cncr.11320" @default.
• W2001468622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12712486" @default.
• W2001468622 hasPublicationYear "2003" @default.
• W2001468622 type Work @default.
• W2001468622 sameAs 2001468622 @default.
• W2001468622 citedByCount "209" @default.
• W2001468622 countsByYear W20014686222012 @default.
• W2001468622 countsByYear W20014686222013 @default.
• W2001468622 countsByYear W20014686222014 @default.
• W2001468622 countsByYear W20014686222015 @default.
• W2001468622 countsByYear W20014686222016 @default.
• W2001468622 countsByYear W20014686222017 @default.
• W2001468622 countsByYear W20014686222018 @default.
• W2001468622 countsByYear W20014686222019 @default.
• W2001468622 countsByYear W20014686222020 @default.
• W2001468622 countsByYear W20014686222021 @default.
• W2001468622 countsByYear W20014686222022 @default.
• W2001468622 crossrefType "journal-article" @default.
• W2001468622 hasAuthorship W2001468622A5002258748 @default.
• W2001468622 hasAuthorship W2001468622A5015616162 @default.
• W2001468622 hasAuthorship W2001468622A5024094034 @default.
• W2001468622 hasAuthorship W2001468622A5028379207 @default.
• W2001468622 hasAuthorship W2001468622A5034364804 @default.
• W2001468622 hasAuthorship W2001468622A5037398995 @default.
• W2001468622 hasAuthorship W2001468622A5045814115 @default.
• W2001468622 hasAuthorship W2001468622A5048487071 @default.
• W2001468622 hasAuthorship W2001468622A5061133224 @default.
• W2001468622 hasAuthorship W2001468622A5063230516 @default.
• W2001468622 hasAuthorship W2001468622A5073906112 @default.
• W2001468622 hasBestOaLocation W20014686221 @default.
• W2001468622 hasConcept C118303440 @default.
• W2001468622 hasConcept C126322002 @default.
• W2001468622 hasConcept C142724271 @default.
• W2001468622 hasConcept C168563851 @default.
• W2001468622 hasConcept C170493617 @default.
• W2001468622 hasConcept C197934379 @default.
• W2001468622 hasConcept C202871150 @default.
• W2001468622 hasConcept C203092338 @default.
• W2001468622 hasConcept C204787440 @default.
• W2001468622 hasConcept C27081682 @default.
• W2001468622 hasConcept C2776533618 @default.
• W2001468622 hasConcept C2777170512 @default.
• W2001468622 hasConcept C2778375690 @default.
• W2001468622 hasConcept C2779924295 @default.
• W2001468622 hasConcept C2780401358 @default.
• W2001468622 hasConcept C2780574406 @default.
• W2001468622 hasConcept C2780580376 @default.
• W2001468622 hasConcept C2780852908 @default.
• W2001468622 hasConcept C2780884295 @default.
• W2001468622 hasConcept C2781413609 @default.
• W2001468622 hasConcept C42219234 @default.
• W2001468622 hasConcept C71924100 @default.
• W2001468622 hasConcept C98274493 @default.
• W2001468622 hasConceptScore W2001468622C118303440 @default.
• W2001468622 hasConceptScore W2001468622C126322002 @default.
• W2001468622 hasConceptScore W2001468622C142724271 @default.
• W2001468622 hasConceptScore W2001468622C168563851 @default.

• next